Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Down 17.4% in September

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 1,900 shares, a decrease of 17.4% from the August 31st total of 2,300 shares. Based on an average daily volume of 3,600 shares, the short-interest ratio is currently 0.5 days.

Santen Pharmaceutical Price Performance

OTCMKTS SNPHY remained flat at $12.66 during trading hours on Friday. The company’s stock had a trading volume of 343 shares, compared to its average volume of 7,086. Santen Pharmaceutical has a fifty-two week low of $8.31 and a fifty-two week high of $13.00. The company’s 50 day moving average is $12.15 and its 200 day moving average is $10.77.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.